Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Comprehensive Biodistribution Assessment in Large Animal Models for Gene Therapy Safety Studies in EMEA

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Comprehensive Biodistribution Assessment in Large Animal Models for Gene Therapy Safety Studies in EMEA

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What quantitative methods are standard for AAV vector DNA quantification?

    A: We primarily employ quantitative PCR (qPCR) and droplet digital PCR (ddPCR) for absolute quantification of vector DNA in collected tissues. ddPCR offers higher precision and is particularly valuable for detecting low copy numbers in non-target tissues, a key data point for regulatory safety assessments.

    How does Franklin Biolabs mitigate the impact of pre-existing neutralizing antibodies (NAbs)?

    A: We conduct rigorous, serotype-specific NAb screening on all large animal cohorts prior to study initiation. This allows for the selection of seronegative animals or the appropriate stratification of study groups, ensuring that pre-existing immunity does not confound the biodistribution and transduction efficiency data.

    What is a typical tissue collection list for a gene therapy biodistribution study?

    A: A standard panel includes the target organ(s), injection site, gonads, liver, spleen, kidney, heart, lung, brain, spinal cord, and draining lymph nodes. The final list is customized based on the AAV serotype, route of administration, and specific safety concerns outlined by EMA or other regulatory bodies.

    How are study designs aligned with EMA expectations?

    A: Our study directors, in collaboration with our strategic regulatory partners, design protocols that directly address EMA guidelines for gene therapy products. This includes considerations for vector shedding, germline transmission risk, and long-term expression, ensuring the generated data package is comprehensive and submission-ready.

Executive Summary

For gene therapy developers targeting the EMEA market, comprehensive biodistribution data from a relevant large animal model is a required component for the Investigational Medicinal Product Dossier (IMPD). These studies must quantify vector DNA persistence, distribution to target and non-target tissues, and potential for shedding. We execute these GxP-compliant studies by integrating mandatory pre-screening for neutralizing antibodies (NAbs) with highly sensitive quantitative assays (ddPCR/qPCR) to generate a data package that directly supports a favorable safety profile for regulatory review.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

The Significance of Pre-existing Immunity Screening

The selection of a translational large animal model introduces a significant biological variable: pre-existing immunity to AAV capsids. As demonstrated in preclinical research, the presence of NAbs can effectively block vector transduction in vivo, rendering biodistribution data uninterpretable (PMID: 26067568).

A failure to account for this variable can lead to incorrect conclusions about vector tropism and dose response. Our standard protocol mandates a robust NAb screening phase for all large animal cohorts to:

  • Ensure the selection of seronegative animals for study.

  • Prevent the loss of valuable data due to vector neutralization.

  • Provide a clean baseline for evaluating the vector’s intrinsic distribution profile.

Designing Robust GxP Biodistribution Protocols

A successful biodistribution study quantifies vector delivery with precision. The protocol must be meticulously designed to capture vector copy numbers across a wide range of tissues at multiple time points.

Our approach includes:

  • Comprehensive Tissue Collection: A scientifically justified list of tissues, including target organs, gonads, and major organ systems, is collected under strict GxP conditions.

  • Sensitive Molecular Assays: We utilize qualified qPCR and ddPCR assays to provide absolute quantification of vector DNA, capable of detecting minimal copy numbers in non-target tissue.

  • Integrated Histology: Molecular data is supported by Histology and in situ hybridization (ISH) to confirm cellular localization and assess any tissue-level pathological findings.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Animal Welfare and GxP Compliance

Our programs are designed to meet and exceed the standards set by AAALAC and the USDA, with all protocols reviewed and approved by our Institutional Animal Care and Use Committee (IACUC). We fully embrace the 3Rs principles (Replacement, Reduction, Refinement) as a core component of our scientific and ethical framework.

Translating Data into a Coherent Safety Narrative

The primary purpose of a biodistribution study is to build a key part of the safety case for your therapeutic candidate. The data must clearly demonstrate controlled delivery to target tissues with minimal and non-consequential presence in non-target organs. This is a prerequisite for demonstrating a favorable safety profile, a concept validated in successful gene therapy programs that have progressed to clinical evaluation (PMID: 35333110).

Within our >100,000 sq ft GxP-compliant facility, our teams work to generate this data within an 18-24 month IND-enabling timeline. This focused execution has contributed to a 100% IND/IMPD success rate for programs conducted since 2019. (The Franklin Biolabs brand launched in 2024).

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities